Through a diversified and differentiated business model of marketing, out-licensing with supply agreements and contract manufacturing, Intas has achieved PAN European presence. Intas’ core strategy in Europe has been to leverage its hospital network for own/in the licensed pipeline of injectables and target marketing of oral generics in markets of North/West Europe. The acquisition of Actavis UK and Ireland business in 2016 catapulted Intas amongst the top 3 players in the UK and Ireland Generics market.
In total, Intas has 8,500+ product registrations in the European market and strong product pipeline for day 1 launch of products in the market. Intas is a leader in the oncology market with a supportive product basket for every stage and indication of cancer. The company currently has 35 oncology molecules in the market with 5 more planned over the next 12 months.
Intas’ exceptional European pipeline consists of a complex product portfolio. Over 4000 product launches including exclusive 60 day 1 launches are planned in the next 5 years.
Headquartered in Durham, North Carolina, Intas’ US operations are currently generating around USD $350Mn in revenues. Despite pricing pressure and customer base consolidation, Intas has achieved continual growth and improved ranking, year on year. Intas has also gained superior positioning in the US markets with some of its products leading various categories. Today, Intas is one of the leading pharmaceutical companies in the US generics market by prescription volume. It is also the preferred supplier for leading retailers, distributors, wholesalers, GPOs and the integrated health systems.
The company has achieved significant market share in more than half of its 118 approved ANDAs, covering niche therapies like oncology, immunosuppressants and other critical care segments. Going forward, a strategic differentiated pipeline of niche and complex dosage forms is set to drive its future growth.
Currently ranked at 8th (as per IQVIA TSA MAT July 2021) in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 3.1% market share. Driven by a sustainable business model, Intas has been consistently outperforming the market with a 13.1% CAGR. Its 8 Strategic Business Units employ a multidivisional model, with 40+ marketing divisions catering to various therapy areas for enhanced focus towards brand development. On the foundation of this diversified revenue base, Intas has gained a dominant presence in India with an expanding market share and improving ranks across years.
50% of Intas’ total domestic revenue is generated from Neurology, Psychiatry and Cardiovascular therapies. The current emphasis is on Central Nervous System (CNS), Nephrology, Cardiovascular, Diabetology, Gastroenterology, Urology and Pain Management therapies. While Intas enjoys leadership status in the CNS segment, it has also been rapidly gaining equity in Oncology, Rheumatology, Ophthalmology, Dermatology and Infertility segments. Intas enjoys exhaustive coverage of key specialties like Neurologists, Psychiatrists, Cardiologists, Diabetologists, Consulting Physicians, Urologists, Nephrologists & Oncologists with a substantial* prescriber base. The company is set to enhance its presence in the market through its active progress in NDDS. Currently, Intas has launched 3 NDDS products in India using patented technology.
Intas is also one of the renowned leaders in animal healthcare companies in India, specializing in large animals and pet segments. Intas Animal Health is determined to make a difference in the prospects of animal health care by launching innovative products for the livestock, companion animals, equine, swine and poultry while also taking educational initiatives, and sponsoring programs that address current and emerging animal health needs.
Apart from USA and Europe operation, Intas has significant presence in various countries like Canada, Brazil, Mexico, Latam Countries, MENA Countries, Australia, New Zealand, South Africa, Asia-Pac and Africa. The focus remains on expanding business in the pharmerging market with the help its strong product basket and pipeline. Each country is supported with local regulatory team and infrastructure for registration of products. For marketing, Intas’ products have entered into out-licensing and long term supply agreements with multinational and strong local generic companies.